Search Within

GME, Medicine

Formats
  1. Meeting Abstract (757)
  2. Journal Article (571)
  3. Review (146)
  4. Editorial (65)
  5. Research Letter (61)
  6. Correspondence (24)
  7. Guidelines (6)
  8. Miscellaneous (6)
  9. Book Section (5)
  10. Conference Paper (4)
Groups
  1. Graduate Medical Education (1645)
  2. Department of Medicine (1296)
  3. Hematology-Oncology Fellows (1096)
  4. Hematologic Malignancies, Division of (779)
  5. Solid Tumor Oncology Division (649)
  6. Weinberg Fellows (623)

More Groups

People
  1. Gunjan Shah (156)
  2. Kylee Maclachlan (155)
  3. Michael Scordo (148)
  4. Saad Usmani (136)
  5. Sergio Giralt (134)
  6. Alexander Lesokhin (120)

More People

Years
  1. 2025 (173)
  2. 2024 (426)
  3. 2023 (404)
  4. 2022 (323)
  5. 2021 (154)
  6. 2020 (73)

More Years

Publications
  1. Blood (311)
  2. Journal of Clinical Oncology (234)
  3. Clinical Lymphoma, Myeloma and Leukemia (46)
  4. Clinical Cancer Research (43)
  5. Annals of Oncology (37)
  6. Blood Advances (34)

More Publications

Publishers
  1. American Society of Hematology (350)
  2. American Society of Clinical Oncology (272)
  3. Elsevier Inc. (206)
  4. Nature Publishing Group (112)
  5. American Association for Cancer Research (101)
  6. Oxford University Press (70)

More Publishers

Results (1645)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Artificial-intelligence, data-driven, comprehensive classification of myeloid neoplasms based on genomic, morphological and histological features
    Meeting Abstract

    Lanino, L.; D'Amico, S.; Maggioni, G.; Ali, N. H. A.; Wang, Y. H.; Gurnari, C.; Gagelmann, N.; Bewersdorf, J. P.; Ball, S.; Guglielmelli, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Survival and therapeutic outcomes in T-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
    Meeting Abstract

    Braunstein, Z.; McLaughlin, E.; Lingamaneni, P.; Barta, S. K.; Cao, M.; Chang, T.; Ganesan, N.; Luu, B.; Mehta-Shah, N.; Shree, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
    Meeting Abstract

    Thompson, M. C.; Parrondo, R. D.; Frustaci, A. M.; Allan, J. N.; Ghia, P.; Mocanu, I.; Tam, C. S.; Trotman, J.; Ahn, I. E.; Stilgenbauer, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of EPCORE CLL-1
    Meeting Abstract

    Danilov, A.; Fakhri, B.; Awan, F. T.; Bentzen, H. H.; Eradat, H. A.; Niemann, C. U.; Offner, F.; Poulsen, C. B.; Hoeyer, T.; Bellido, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those having European ancestry
    Meeting Abstract

    Maclachlan, K. H.; Papadimitriou, M.; Blaney, P.; Shekarkhand, T.; Chu, T. R.; Poos, A. M.; Brown, E.; Hoering, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save